Euveda's core technology has been extensively tested for numerous cell-based assay applications, and many validation studies have been published in high profile journals (see below).
"High content cell screening in a microfluidic device", Molecular and Cellular Proteomics, 8:433 (2009)
This article describes a prototype version of Euveda's core technology: a microfluidic device that can be used to perform high throughput cell-based assays, including high content cell screening, with very low cell consumption and highly accurate fluid handling. This paper demonstrates that the technology can be used in a wide variety of applications, including analyzing single cells, measuring kinetic and end point cell responses, detecting on- and off-target drug effects, and assaying using complex multi-wash protocols. This paper was highlighted as an Editors' Choice in Science Signaling.
"MAPK-mediated bimodal gene expression and adaptive gradient sensing in yeast", Nature, 446:46 (2007)
This article describes a microfluidic device that enables dose response measurements on non-adherent cells in a microfluidic device. This device was used to study mitogen activated protein kinase signaling at a single cell level, leading to a breakthrough in our understanding of how cells decide between different behaviors (e.g. proliferation versus cell migration).
"Using a microfluidic device for high-content analysis of cell signaling", Science Signaling, 2:pl2 (2009)
(Featured on cover)
This article describes how an end user can implement cell-based assays, including high content cell screening, using our microfluidic technology. This article was highlighted on the cover of Science Signaling.
"Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk", PNAS, 104:20926 (2007).
This article investigates an epigenetic change to the gene for insulin-like growth factor II (IGF-II) which has been linked to an increased risk of developing colon cancer. A major portion of the study involved analysis of mouse primary cells which grew very slowly and whose supply was very limited. We leveraged the extremely low cell consumption of the microfluidic assay to perform a large scale characterization of IGF-II signaling, and identified response dynamics that correlated with epigenetic status.
"Visualization of JNK activity dynamics with a genetically encoded fluorescent biosensor", PNAS, 107:5459 (2010).
This article describes a new live-cell probe for Jun kinase (JNK) activity developed by Jin Zhang (JHU, Pharmacology) and colleagues. For this study, the high-throughput capability of Euveda's microfluidic technology was leveraged to examine the dynamics of JNK activation at a single cell level. Our results confirmed other observations of ultrasensitive and bimodal responses in the JNK signaling pathway.
"High-content screening in microfluidic devices", Expert Opinion on Drug Discovery, 5:715 (2010).
This article reviews the advantages of using microfluidic technology in drug screening applications.